<SEC-DOCUMENT>0001178913-22-000515.txt : 20220210
<SEC-HEADER>0001178913-22-000515.hdr.sgml : 20220210
<ACCEPTANCE-DATETIME>20220210070738
ACCESSION NUMBER:		0001178913-22-000515
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20220210
FILED AS OF DATE:		20220210
DATE AS OF CHANGE:		20220210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InMode Ltd.
		CENTRAL INDEX KEY:			0001742692
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39016
		FILM NUMBER:		22609548

	BUSINESS ADDRESS:	
		STREET 1:		TAVOR BUILDING, SHA?AR YOKNEAM
		STREET 2:		POB 533
		CITY:			YOKNEAM
		STATE:			L3
		ZIP:			2069200
		BUSINESS PHONE:		972-4-9097470

	MAIL ADDRESS:	
		STREET 1:		TAVOR BUILDING, SHA?AR YOKNEAM
		STREET 2:		POB 533
		CITY:			YOKNEAM
		STATE:			L3
		ZIP:			2069200
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2227245.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div id="DSPFPageHeader">
      <div style="line-height: 1.25;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-style: normal; font-variant: normal; text-transform: none;">SECURITIES AND EXCHANGE COMMISSION</font><br>
      WASHINGTON, D.C. 20549</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM 6-K</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER<br>
      PURSUANT TO RULE 13a-16 OR 15d-16 OF<br>
      THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">For the month of February 2022</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 50%; color: #000000; text-align: center;"></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">INMODE LTD.</div>
    <div style="text-align: center; line-height: 1.25;">(Exact name of registrant as specified in its charter)</div>
    <div style="text-align: center; line-height: 1.25;">
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 50%; color: #000000;"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Tavor Building, Sha&#8217;ar Yokneam</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;P.O. Box 533</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Yokneam 2069206&#160;Israel</div>
    <div style="text-align: center; line-height: 1.25;">(Address of Principal Executive Offices)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z61284bef932e40e1b0b47f3bbcad0c86">

        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Form 20-F &#9746; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Form 40-F &#9744;&#160;</font></div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
      Securities Exchange Act of 1934:</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z142bcaf088f94bbf958c2cecfa8ded3d">

        <tr>
          <td rowspan="1" style="width: 0.59%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Yes &#9744; &#160; &#160; &#160;&#160; No &#9746;&#160;</font></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">On February 10, 2022, InMode Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) announced that it will hold its Annual General Meeting of the Shareholders of the Company on Monday, April 4,
      2022, beginning at 17:00, Israel time, at the offices of the Company located at Tavor Building, Sha&#8217;ar Yokneam Industrial Park, Yokneam, Israel. A copy of the proxy statement is attached hereto as Exhibit 99.1.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z70cad28461a246b986b2316ba7b1bf84">

        <tr>
          <td style="width: 13.93%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;"><u>Exhibit No.</u></div>
          </td>
          <td style="width: 86.07%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;"><u>Description of Exhibit</u></div>
            <div style="line-height: 1.25; font-weight: bold;"><u> <br>
              </u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.93%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">99.1</a></div>
          </td>
          <td style="width: 86.07%; vertical-align: top;">
            <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">Proxy Statement dated February 10, 2022</a></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
      authorized.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zc27b442d0c8b4e9580d327d6e8afa9ab">

        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25; font-weight: bold;">InMode Ltd.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">By:<u>/s/ Moshe Mizrahy</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Moshe Mizrahy</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">&#160;</td>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Executive Officer and Chairman of</div>
            <div style="line-height: 1.25;">The Board of Directors</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">Dated February 10, 2022</div>
    <div style="line-height: 1.25;"><br>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><br>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div id="DSPFPageHeader">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
      <div style="line-height: 1.25; text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25;"><img width="362" height="149" src="image0.jpg"></div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Tavor Building, Sha'ar Yokneam, P.O. Box 533, Yokneam 2069206, Israel</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: right; line-height: 1.25;">February 10, 2022</div>
    <div style="text-align: justify; line-height: 1.25;">Dear Shareholder,</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You are cordially invited to attend an annual general meeting (the &#8220;<font style="font-weight: bold;">Meeting</font>&#8221;) of the shareholders of InMode Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), to be held on Monday, April 4, 2022, beginning at 17:00, Israel time, at the offices of the Company located at Tavor Building, Sha'ar Yokneam Industrial Park, Yokneam, Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Company&#8217;s notice of the Meeting, as published on February 10, 2022, and the proxy statement (&#8220;<font style="font-weight: bold;">Proxy Statement</font>&#8221;) included within the
      following pages, describe in detail the matters to be acted upon at the Meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Only shareholders who held shares at the close of business on February 25, 2022, are entitled to notice of, and to vote at, the Meeting and any adjournment or postponement thereof.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">The Company's board of directors recommends a vote &#8220;FOR&#8221; each of the matters set forth in the notice.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">Whether or not you plan to attend the Meeting, it is important that your shares be represented and voted at the Meeting. Shareholders are urged to complete and
      return their proxies promptly in order to, among other things, ensure action by a quorum and to avoid the expense of additional solicitation. Accordingly, after reading the enclosed Notice of Annual General Meeting of Shareholders and accompanying
      Proxy Statement, please sign, date, and mail the enclosed proxy card by means of the envelope provided, or otherwise vote by telephone or over the internet in accordance with the instructions given in your proxy card.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We look forward to seeing as many of you as can attend the Meeting.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" align="right" style="width: 50%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z4e59eddcd10c43908c439de15caa0f6b">

        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Very truly yours,</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: justify; line-height: 1.25;">/s/ Moshe Mizrahy</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Moshe Mizrahy</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">CEO and Chairman of the Board of Directors</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; clear: both;"><br style="line-height: 1.25;">
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">INMODE LTD.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">Tavor Building, Sha'ar Yokneam, P.O. Box 533, Yokneam 2069206, Israel</div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Tel: +972-4-909-6313</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;">To be held on April 4, 2022</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Notice is hereby given to the holders of ordinary shares, nominal value NIS 0.01 per share, of&#160;InMode Ltd. (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;) in connection
      with the solicitation by the board of directors of the Company (the &#8220;<font style="font-weight: bold;">Board</font>&#8221;) of proxies for use at the annual general meeting of its shareholders (the &#8220;<font style="font-weight: bold;">Meeting</font>&#8221;) to be
      held on&#160;Monday, April 4, 2022, at 17:00 Israel time, at the offices of the Company at Tavor Building, Sha'ar Yokneam Industrial Park, Yokneam, Israel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Meeting is being called for the following purposes:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to re-elect each of Mr. Moshe Mizrahy and Dr. Michael Kreindel to serve as a Class III director of the Company, and to hold office until the close of business of
      the annual general meeting of shareholders to be held in 2025&#160;and until their respective successors are duly elected and qualified, or until such individual's earlier resignation or retirement; and</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to approve an increase in the number of the Company's authorized ordinary shares and authorized share capital, and to amend and restate the Articles of Association
      of the Company to reflect such increase.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to approve the re-appointment of Kesselman &amp; Kesselman Certified Public Accounts, a member of PwC, as the Company&#8217;s independent auditors for the fiscal year
      ending December 31, 2022, and its service until the annual general meeting of shareholders to be held in 2023.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">(4)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to approve the grant to each of our following directors: Dr. Michael Anghel, Mr. Bruce Mann and Dr. Hadar Ron, of 2,000 restricted share units under the Company's
      2018 Incentive Plan totaling 6,000 restricted share units, half of which shall vest on December 31, 2022, and the remaining half shall vest on December 31, 2023.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The Board recommends that the shareholders vote in favor of each of the above proposals, which will be described in a proxy statement to be made available to the Company&#8217;s
      shareholders.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">In addition, shareholders attending the Meeting will have an opportunity to review and ask questions regarding the financial statements of the Company for the fiscal year ended
      December 31, 2021.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We are currently not aware of any other matters that will come before the Meeting. If any other matters are presented properly at the Meeting,&#160;it is intended that&#160;the persons
      designated as proxies will vote upon such matters in accordance with their best judgment&#160;and the interest of the Company.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">In accordance with the Israeli Companies Law 5759-1999, and regulations promulgated thereunder (the &#8220;<font style="font-weight: bold;">Companies Law</font>&#8221;), any shareholder of
      the Company holding at least 1% (one percent) of the outstanding voting rights of the Company for the Meeting may submit to the Company a proposed additional agenda item for the Meeting in accordance with Section 66(b) of the Companies Law, no later
      than February 17, 2022, and for all other agenda items, no later than February 13, 2022. To the extent that there are any additional agenda items that the Board determines to add as a result of any such submission, the Company will publish an updated
      agenda and proxy card with respect to the Meeting, no later than February 24, 2022 with respect to proposed additional agenda items in accordance with Section 66(b) of the Companies Law, and no later than February 20, 2022 with respect to all other
      proposed additional agenda items.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The presence (in person or by proxy) of any two or more shareholders holding, in the aggregate, at least 25% of the voting rights in the Company, constitutes a quorum for
      purposes of the Meeting. In the absence of the requisite quorum of shareholders at the Meeting, the Meeting will be adjourned to Monday, April 11, 2022, at the same time and place, unless otherwise determined at the Meeting in accordance with the
      Company&#8217;s articles of association. At such adjourned meeting the presence of any shareholder in person or by proxy (regardless of the voting power represented by his/her/it shares) will constitute a quorum.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Only shareholders of record at the close of business on Friday, February 25, 2022, are entitled to notice of, and to vote at, the Meeting, or at any adjournment or postponement
      thereof.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Approval of each of Proposals 1, 2, 3 and 4 requires the affirmative vote of the holders of a majority of the voting power represented at the Meeting or at any adjournment
      thereof in person or by proxy and voting thereon.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">A proxy statement describing the various matters to be voted upon at the Meeting along with a proxy card enabling the shareholders&#160;to&#160;indicate their vote on each matter will be
      mailed on or about March 7, 2022, to all shareholders entitled to participate in and vote at the Meeting. Such proxy statement will also be&#160;publicly filed with&#160;the U.S. Securities and Exchange Commission (the &#8220;<font style="font-weight: bold;">SEC</font>&#8221;)






      under cover of Form 6-K and will be available on the&#160;Company&#8217;s&#160;website&#160;<u>www.inmodemd.com</u>. Proxies must be submitted to the Company or to its transfer agent no later than midnight on the night prior to the Meeting.&#160;Proxies delivered to the
      Company or to its transfer agent after such time will be presented to the chairperson of the Meeting and, at his discretion, may be voted as specified in the instructions included in such proxies. If your ordinary shares in the Company are held in
      &#8220;street name&#8221; (meaning held through a bank, broker or other nominee), you will be able to either direct the record holder of your shares on how to vote your shares or obtain a legal proxy from the record holder that enabled you to participate in and
      to vote your shares at the Meeting (or to appoint a proxy to do so).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">In accordance with the Israeli Companies Law, any shareholder of the Company&#160;may&#160;submit to the Company a position statement on its behalf, expressing its position on any, some
      or all agenda items for the Meeting, either via mail to the Company&#8217;s offices at Tavor Building, Sha'ar Yokneam, P.O. Box 533, Yokneam 2069206, Israel, Attention: Rafael Lickerman, VP Finance, or by e-mail to Rafael.Lickerman@inmodemd.com, no later
      than March 27, 2022. Reasonable costs incurred by the Company in dealing with a position statement shall be borne by the submitting shareholder. Any position statement received will be furnished to the SEC on Form 6-K, and will be made available to
      the public on the SEC&#8217;s website at <font style="font-weight: bold;"><u>http://www.sec.gov</u></font>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" align="right" style="width: 50%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z18b379f4352a4781a2ce5263c592ad3b">

        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">BY ORDER OF THE BOARD OF DIRECTORS</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: justify; line-height: 1.25;">/s/ Moshe Mizrahy</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Moshe Mizrahy</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">CEO and Chairman of the Board of Directors</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; clear: both;">&#160;</div>
    <div style="line-height: 1.25;">February 10, 2022</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25; text-align: center;">- ii -<br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">INMODE LTD.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">Tavor Building, Sha'ar Yokneam, P.O. Box 533, Yokneam 2069206, Israel</div>
    </div>
    <div style="text-align: center; line-height: 1.25;">Tel: +972-4-909-6313</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROXY STATEMENT</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">General Information</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">This proxy statement (the &#8220;<font style="font-weight: bold;">Proxy Statement</font>&#8221;) and the accompanying proxy card are being furnished to the holders of ordinary shares,
      nominal value NIS 0.01 per share, of InMode Ltd., an Israeli company (the &#8220;<font style="font-weight: bold;">Company</font>&#8221;), in connection with the solicitation of proxies by the board of directors of the Company (the &#8220;<font style="font-weight: bold;">Board</font>&#8221;), for use at the annual general meeting of shareholders of the Company (the &#8220;<font style="font-weight: bold;">Meeting</font>&#8221;) to be held on&#160;Monday, April 4, 2022, beginning at 17:00 Israel time, at the offices of the Company
      at Tavor Building, Sha'ar Yokneam Industrial Park, Yokneam, Israel.&#160;You are entitled to notice of, and to vote at, the Meeting, if you hold ordinary shares as of the close of business on&#160;Friday, February 25, 2022, the record date for the Meeting (the
      &#8220;<font style="font-weight: bold;">Record Date</font>&#8221;).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">The Proxy</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Each of Moshe Mizrahy and Yair Malca may be appointed as proxies by the shareholders entitled to vote at the Meeting with respect to the matters to be voted upon at the Meeting.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">All ordinary shares represented by properly executed proxies delivered to the Company's transfer agent, American Stock Transfer &amp; Trust Company, or to the Company by mail at
      its offices at Tavor Building, Sha'ar Yokneam, P.O. Box 533, Yokneam 2069206, Israel, Attention: Rafael Lickerman, VP Finance, or by e-mail to Rafael.Lickerman@inmodemd.com, will be voted as specified in the instructions indicated in such proxies.
      Proxies must be submitted to the Company or to its transfer agent no later than midnight on the night prior to the Meeting. Proxies delivered to the Company or to its transfer agent after such time will be presented to the chairperson of the Meeting
      and, at his discretion, may be voted as specified in the instructions included in such proxies.&#160;If you are a shareholder of record as of the record date for the Meeting, subject to applicable law and the rules of the Nasdaq Global Select Market (&#8220;<font style="font-weight: bold;">Nasdaq</font>&#8221;), if no instructions are indicated in such proxies with respect to the Proposal, the shares represented by properly executed and received&#160;proxies will be voted &#8220;FOR&#8221; each of the Proposals. If you hold your
      shares in &#8220;street name&#8221; through a broker, bank or other nominee, you are considered, with respect to those shares, a beneficial owner. Absent specific instructions from the beneficial owner of the shares, brokers are not allowed to exercise their
      voting discretion with respect to any items presented at the Meeting, as described below.&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Revocation of Proxies</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">A shareholder may revoke a proxy in one of the following ways: (i) by written notice of the revocation of the proxy delivered to the Company's transfer agent, American Stock
      Transfer &amp; Trust Company, or by mail to the Company at its offices<font style="font-weight: bold;">&#160;</font>at Tavor Building, Sha'ar Yokneam, P.O. Box 533, Yokneam 2069206, Israel, Attention: Rafael Lickerman, VP Finance, or by e-mail to
      Rafael.Lickerman@inmodemd.com, before midnight on the night prior to the time of the Meeting canceling the proxy or appointing a different proxy, (ii) by written notice of the revocation of the proxy delivered at the Meeting to the chairman of the
      Meeting, or (iii) by&#160;attending&#160;and voting in person at the Meeting. Attendance at the Meeting will not in and of itself constitute revocation of a proxy.</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"> <br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Shareholders Entitled to Vote &#8211; Record Date</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Shareholders of record who held ordinary shares at the close of business on Friday, February 25, 2022, are entitled to notice of, and to vote at, the Meeting. In addition,
      shareholders who, as of the Record Date, held ordinary shares through a bank, broker or other nominee which is a shareholder of record of the Company at the close of business on the Record Date, or which appears in the participant list of a
      securities depository on that date, are considered to be beneficial owners of shares held in &#8220;street name&#8221;. These proxy materials are being forwarded to beneficial owners by the bank, broker or other nominee that is considered the holder of record
      with respect to the Company&#8217;s ordinary shares. Beneficial owners have the right to direct how their shares should be voted and are also invited to attend the Meeting, but may not actually vote their shares in person at the Meeting unless they first
      obtain a signed proxy from the record holder (that is, their bank, broker or other nominee) giving them the right to vote the shares.</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">As of January 25, 2022, there were 83,241,221 ordinary&#160;shares&#160;issued, outstanding and entitled to vote at the Meeting.</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Quorum and Required Vote</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Pursuant to the Company&#8217;s articles of association, the quorum required for the Meeting consists of at least two shareholders present, in person or by proxy, who hold or
      represent between them at least 25% of the Company&#8217;s voting power. If a quorum is not present within thirty (30) minutes from the time designated for the Meeting, the Meeting will stand adjourned to Monday, April 11, 2022,&#160;at the same time and place,
      unless otherwise determined at the Meeting in accordance with the Company&#8217;s articles of association&#160;(the &#8220;<font style="font-weight: bold;">Adjourned Meeting</font>&#8221;).&#160;At such Adjourned Meeting the presence of any shareholder in person or by proxy
      (regardless of the voting power represented by their shares) will constitute a quorum. Any reference in this Proxy Statement to the term Meeting shall include the term &#8220;Adjourned Meeting&#8221; for all purposes.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Abstentions and &#8220;broker non-votes&#8221; are counted as present and entitled to vote for purposes of determining a quorum. A &#8220;broker non-vote&#8221; occurs when a bank, broker or other
      holder of record holding shares for a beneficial owner attends the Meeting but<font style="font-weight: bold;">&#160;</font>does not vote on a particular proposal because that holder does not have discretionary voting power for that particular item and
      has not received instructions from the beneficial owner. Brokers that hold shares in &#8220;street name&#8221; for clients typically have authority to vote on &#8220;routine&#8221; proposals even when they have not received instructions from beneficial owners. Absent
      specific instructions from the beneficial owner of the shares, however, brokers are not allowed to exercise their voting discretion with respect to any proposals that are considered non-routine. If you hold your shares in &#8220;street name&#8221; and do not
      provide your broker with specific instructions regarding how to vote on any proposal, your broker will not be permitted to vote your shares on the proposal, resulting in a &#8220;broker non-vote&#8221;. Therefore,&#160;it is important for a shareholder that
      holds&#160;ordinary&#160;shares through a bank or broker to instruct its&#160;bank&#160;or&#160;broker&#160;how to vote its shares, if the shareholder wants its shares to count for all proposals.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Approval of each of Proposals 1, 2, 3 and 4 requires the affirmative vote of the holders of a majority of the ordinary shares represented at the Meeting or at any adjournment
      thereof in person or by proxy and voting thereon.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The Board recommends shareholders vote &#8220;<font style="font-weight: bold;">FOR</font>&#8221; each of the Proposals set forth in the Proxy Statement.</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Except for the purpose of&#160;determining&#160;a quorum, broker non-votes will not be counted as present and are not entitled to vote. Abstentions will not be treated as either a vote &#8220;FOR&#8221;
      or &#8220;AGAINST&#8221; a matter.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">On each matter submitted to the shareholders for consideration at the Meeting, only ordinary shares that are voted on such matter will be counted toward determining whether
      shareholders approved the matter. Ordinary shares present at the Meeting that are not voted on a particular matter (including broker non-votes) will not be counted in determining whether such matter is approved by shareholders.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each ordinary share is entitled to one vote on each proposal or item that comes before the Meeting. If two or more persons are registered as joint owners of any ordinary share, the
      right to vote at the Meeting and/or the right to be counted as part of the quorum thereat will be conferred exclusively upon the more senior among the joint owners attending the Meeting in person or by proxy. For this purpose, seniority will be
      determined by the order in which the names appear in the Company&#8217;s Register of Shareholders.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">How You Can Vote</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">You can vote your shares by attending the Meeting. If you do not plan to attend the Meeting, the method of voting will differ for shares held as a record holder and shares held in
      &#8220;street name&#8221; (through a broker, trustee or nominee). Record holders of shares will receive proxy cards. Holders of shares in &#8220;street name&#8221; will receive either proxy cards or voting instruction cards directly from their bank, broker or nominee in
      order to instruct their banks, brokers or other nominees on how to vote.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Shareholders of Record</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If you are a shareholder of record (that is, you hold a share certificate that is registered in your name or you are listed as a shareholder in the Company&#8217;s share register), you
      can submit your vote by completing, signing and submitting a proxy card, which has or will be sent to you and which will be accessible at the Investors section of the Company&#8217;s website, as described below under &#8220;Availability of Proxy Materials&#8221;.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Please follow the instructions on the proxy card. If you provide specific instructions (by marking a box) with regard to the proposals, your shares will be voted as you instruct.
      The persons named as proxies in the enclosed proxy card will furthermore vote in accordance with the recommendations of the Board on any other matters that may properly come before the Meeting.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Shareholders Holding in &#8220;Street Name&#8221;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If you hold the Company's ordinary shares in &#8220;street name&#8221;, that is, you are an underlying beneficial holder who holds ordinary shares through a bank, broker or other nominee, the
      voting process will be based on your directing the bank, broker or other nominee to vote the ordinary shares in accordance with the voting instructions on your voting instruction card. Because a beneficial owner is not a shareholder of record, you
      may not vote those shares directly at the Meeting unless you obtain a &#8220;legal proxy&#8221; from the bank, broker or nominee that holds your shares, giving you the right to vote the shares at the Meeting.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Please follow the instructions on the voting instruction card received from your bank, broker or nominee. You may also be able to submit voting instructions to a bank, broker or
      nominee by phone or via the Internet if your voting instruction card describes such voting methods. Please be certain to have your control number from your voting instruction card ready for use in providing your voting instructions.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">It is important for a shareholder that holds ordinary shares through a bank or broker to instruct its bank or broker how to vote its shares if the shareholder wants its shares to
      count for the proposal.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Voting Results</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The preliminary voting results will be announced at the Meeting. The final voting results will be tallied by the Company's legal counsels, based on the information provided by
      the Company's transfer agent or otherwise and will be published following the Meeting on a Form 6-K that will be publicly filed with the SEC.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Proxy Solicitation</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The Company will bear the costs of solicitation of proxies for the Meeting. In addition to solicitation by mail, directors, officers, employees and agents of the Company may
      solicit proxies from shareholders by telephone, emails, personal interview or otherwise. Such directors, officers, employees and agents will not receive additional compensation, but may be reimbursed for reasonable out-of-pocket expenses in
      connection with such solicitation. Brokers, nominees, fiduciaries and other custodians have been requested to forward soliciting material to the beneficial owners of ordinary shares held of record by them, and such custodians will be reimbursed by
      the Company for their reasonable out-of-pocket expenses. The Company has retained the services of Georgeson LLC, to assist in the solicitation of proxies. The costs for such services, in the estimated amount of US $13,500<font style="font-weight: bold;">&#160;</font>plus telephone solicitation fees and reimbursement of expenses, will be paid by the Company. Proxies must be submitted to the Company or to its transfer agent no later than midnight on the night prior to the Meeting. Proxies
      delivered to the Company or to its transfer agent after such time will be presented to the chairperson of the Meeting and, at his discretion, may be voted as specified in the instructions included in such proxies.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">If you have questions about this Proxy Statement or the Meeting, please contact our proxy solicitor Georgeson LLC, 1290 Avenue of the Americas, 9<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor, New York,
      NY 10104, U.S.A, by telephone (toll-free) at 888-613-9817 (shareholders, banks and brokers) and +1 781-575-2137 (international number).</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Availability of Proxy Materials</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">Copies of the proxy card, the Notice of the Annual Meeting of Shareholders and this Proxy Statement are available at the Investors section of our Company&#8217;s website at&#160;<u>www.inmodemd.com</u>.
      The contents of that website are not a part of this Proxy Statement.</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">COMPENSATION OF EXECUTIVE OFFICERS AND DIRECTORS</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">
        <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">For information regarding compensation granted to the Company's executive officers during or with respect to the year ended December 31, 2021, please see Item 6 B. of our
          annual report on Form 20-F for the year ended December 31, 2021, which was filed with the SEC on February 10, 2022, and is accessible through the Company&#8217;s website at&#160;<u>www.inmodemd.com</u>&#160;or through the SEC&#8217;s website at&#160;<font style="font-weight: bold;"><u>www.sec.gov</u></font>.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">BENEFICIAL OWNERSHIP OF SECURITIES BY CERTAIN</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">BENEFICIAL OWNERS AND MANAGEMENT</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The following table sets forth certain information regarding the beneficial ownership of the Company's ordinary shares as of December 31, 2021, by:</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3929f9305a4f4225ab38e7d1f727ee17">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>each of the Company's directors and executive officers;</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z44d36c7b8f6a46f78cdcf49c40e71d46">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>all of the Company's executive officers and directors collectively as a group; and</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb876a87b74d74feab78eba4d9dea10a5">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>each person (or group of affiliated persons) known by the Company to be the beneficial owner of more than 5% of the outstanding ordinary shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The beneficial ownership of the Company's ordinary shares is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of
        a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the disposition of the security. For purposes
        of the table below, we deem ordinary shares issuable pursuant to options, RSUs or warrants that are currently exercisable or exercisable within 60 days as of December 31, 2021, if any, to be outstanding and to be beneficially owned by the person
        holding the options, RSUs or warrants for the purposes of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. The percentage of
        ordinary shares beneficially owned is based on 82,978,115 ordinary shares outstanding (excluding treasury shares) as of December 31, 2021, according to our transfer agent, and 111,164 ordinary shares exercisable within 60 days of December 31, 2021,
        owned by the above beneficial owners.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Except where otherwise indicated, we believe, based on information furnished to us by such owners and based on public information, that the beneficial owners of the ordinary
        shares listed below have sole investment and voting power with respect to such shares. In addition, none of the Company's shareholders have different voting rights from other shareholders. To the best of our knowledge, we are not controlled,
        directly or indirectly, by another corporation or by any foreign government. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Unless otherwise noted below, the address of each shareholder, director and executive officer is c/o InMode Ltd., Tavor Building, Sha'ar Yokneam, P.O. Box 533, Yokneam 2069206, Israel.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z2a7f785a46ef42ff8f4c4758d02a74b4" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-weight: bold;">Name of Beneficial Owner:</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number of Ordinary Shares</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Percentage of Ordinary Shares</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -18pt; margin-left: 18pt; line-height: 1.25;"><font style="font-weight: bold;">5%</font>&#160;<font style="font-weight: bold;">or Greater Beneficial Owners (other than Directors and Executive Officers)</font></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="text-indent: -18pt; margin-left: 18pt; line-height: 1.25;">BoomerangFX International SRL <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">8,123,440</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">9.78</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="text-indent: -18pt; margin-left: 18pt; line-height: 1.25; font-weight: bold;">Directors and Executive Officers</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="margin-left: 9pt; line-height: 1.25;">Dr. Michael Kreindel<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">3,464,762</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">4.17</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="margin-left: 9pt; line-height: 1.25;">Moshe Mizrahy<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)</sup></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">2,006,030</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">2.41</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="margin-left: 9pt; line-height: 1.25;">Dr. Hadar Ron<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">97,030</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="margin-left: 9pt; line-height: 1.25;">Bruce Mann<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">71,940</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%;">
            <div style="margin-left: 9pt; line-height: 1.25;">Dr. Michael Anghel<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">31,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);">
            <div style="margin-left: 9pt; line-height: 1.25;">Yair Malca<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">59,164</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px;">
            <div style="margin-left: 9pt; line-height: 1.25;">Shakil Lakhani<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup></div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">16,500</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;">%</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; font-weight: bold;">Total for all Directors and&#160;Executive Officers as&#160;a Group&#160; (7 persons)</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; font-weight: bold;">5,746,426</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; font-weight: bold;">6.92</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; font-weight: bold;">%</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4b633003793641d388a9109ccfaf894a">

        <tr>
          <td style="width: 21.3pt; vertical-align: top; align: right;">*</td>
          <td style="width: auto; vertical-align: top;">
            <div>Represents beneficial ownership of less than one (1%) percent.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2798b8e0e1cf4653a2d0a81c1cf29164">

        <tr>
          <td style="width: 28.35pt; vertical-align: top; align: right;">(1)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>BoomerangFX International SRL, a Barbados society with restricted liability (&#8220;BoomerangFX&#8221;), directly owned 8,123,440 ordinary shares of the company.&#160; BoomerangFX is a wholly owned direct subsidiary of I.V.C. Enterprises SRL, a Barbados
              society with restricted liability (&#8220;IVC&#8221;), which is a wholly owned direct subsidiary of NEV Property Investments SRL, a Barbados society with restricted liability (&#8220;NEV&#8221;).&#160; NEV is 100% owned by Dr. Stephen Mulholland (together with NEV, IVC
              and BoomerangFX, the &#8220;Reporting Persons&#8221;).&#160; Although the ordinary shares are directly owned by BoomerangFX, each of the Reporting Persons may be deemed to beneficially own such ordinary shares. The address for each of the reporting persons is
              #15 Maxwell Main Road, Christ Church, Barbados BB15042. The beneficial ownership in its entirety is owned as ordinary shares.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z57fa31549c1b4df88d0c20917b340a1f">

        <tr>
          <td style="width: 28.35pt; vertical-align: top; align: right;">(2)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>The beneficial ownership in its entirety is owned as ordinary shares.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z61267c9f7c2c49fdb1d2d3d08f3c7651">

        <tr>
          <td style="width: 28.35pt; vertical-align: top; align: right;">(3)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Dr. Hadar Ron's beneficial ownership consists of: (i) 66,030 ordinary shares, (ii) options to purchase 30,000 ordinary shares, exercisable within 60 days of December 31, 2021, and (iii) 1,000 RSUs, exercisable within 60 days of December
              31, 2021.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zf8933eb31ad54341979a88a55ea6dc49">

        <tr>
          <td style="width: 28.35pt; vertical-align: top; align: right;">(4)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Mr. Bruce Mann's beneficial ownership consists of: (i) 70,940 ordinary shares, and (ii) 1,000 RSUs, exercisable within 60 days of December 31, 2021.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbb8d08687c714812be41eda88d0c0888">

        <tr>
          <td style="width: 28.35pt; vertical-align: top; align: right;">(5)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Mr. Michael Anghel's beneficial ownership consists of: (i) options to purchase 30,000 ordinary shares, exercisable within 60 days of December 31, 2021, and (ii) 1,000 RSUs, exercisable within 60 days of December 31, 2021.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2628b60ee9b2449aae68600535bc7f04">

        <tr>
          <td style="width: 28.35pt; vertical-align: top; align: right;">(6)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Mr. Yair Malca's beneficial ownership consists of: (i) 27,500 ordinary shares, (ii) options to purchase 16,664 ordinary shares, exercisable within 60 days of December 31, 2021, and (iii) 15,000 RSUs, exercisable within 60 days of December
              31, 2021.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze81e111edab74d9c8e45b27bf7e35524">

        <tr>
          <td style="width: 28.35pt; vertical-align: top; align: right;">(7)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>Mr. Shakil Lakhani's beneficial ownership consists of 16,500 RSUs, exercisable within 60 days of December 31, 2021.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">BACKGROUND FOR ELECTION OF DIRECTORS</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Company's Articles of Association, the number of directors on the Company&#8217;s Board is fixed at not less than three (3) and not more than seven (7) members, including
      External Directors (if any were elected). The minimum and maximum number of directors who could be appointed may be changed, at any time and from time to time, by a resolution adopted at the general meeting of the shareholders by a special majority
      of 2/3 of the votes cast excluding abstaining votes. Currently, there are five (5) directors serving on the Board.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the most recent resolution of the shareholders of the Company, our directors are divided into three classes set forth in the Company&#8217;s Articles of Association, as
      follows:</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc95a595745524c79b3b36921154d4dae">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(i)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Class I director is Dr. Hadar Ron, and her term will expire at the annual general meeting of the shareholders to be held in 2023 and when her successor is elected and qualified;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0fc18e29b9a142cba730c8ca7bb002db">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(ii)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Class II directors are Dr. Michael Anghel and Mr. Bruce Mann, and their terms will expire at the annual general meeting of the shareholders to be held in 2024 and when their successors are elected and qualified; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6f3edaa58c4a4bd89c85b5ac65aa5ce1">

        <tr>
          <td style="width: 18pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right;">(iii)</td>
          <td style="width: auto; vertical-align: top; text-align: justify;">
            <div>the Class III directors are Mr. Moshe Mizrahy and Dr. Michael Kreindel, and their terms will expire at the Meeting and when their successors are elected and qualified.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to our Articles of Association, the term of office of the Class III directors, Mr. Moshe Mizrahy and Dr. Michael Kreindel, expires at the Meeting. Any director whose term
      has expired may be re-elected to the Board except as provided by applicable law.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the corporate governance standards of Nasdaq, a majority of our directors must meet the independence requirements specified in those rules. Following the Meeting, assuming
      the election of all nominees, our board of directors will consist of five (5) members, three (3) of whom will be independent under the Nasdaq rules. Specifically, our board of directors determined that Dr. Hadar Ron, Dr. Michael Anghel and Mr. Bruce
      Mann meet the independence standards under the Nasdaq rules. In reaching this conclusion, the board of directors evaluated the relationships between the Company and each of these directors and determined that none of these directors has a
      relationship that would preclude a finding of independence and any relationships that these directors have with the Company do not impair their independence.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In accordance with the exemptions available to foreign private issuers under Nasdaq rules, we are not required to follow the requirements of Nasdaq rules with regard to the process
      of nominating directors. Instead, we are following Israeli law and practice, in accordance with which our board of directors is authorized to recommend to our shareholders director nominees for election or re-election.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At the Meeting, the shareholders will be asked to re-elect Mr. Moshe Mizrahy and Dr. Michael Kreindel as Class III directors, following their nomination by our Compensation,
      Nominating and Corporate Governance Committee and our board of directors.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Company&#8217;s Articles of Association, the directors who are serving in office will be entitled to act even if a vacancy occurs on the Board. However, should the number of
      directors, at the time in question, become&#160;less&#160;than the minimum set forth in our Articles of Association, the remaining director(s) will be entitled to act for the purpose of filling the vacancies which will have occurred on the Board or for
      convening a general meeting, but not for any other purpose.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL ONE</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">RE-ELECTION OF CLASS III DIRECTORS</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;"><u>Background</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our board of directors and compensation, nominating and corporate governance committee have nominated the currently serving Class III directors, Mr. Moshe Mizrahy and Dr. Michael
      Kreindel, for re-election, and our shareholders are being asked to re-elect at the Meeting, each of Mr. Moshe Mizrahy and Dr. Michael Kreindel, to serve as a Class III director of the Company, for an additional term commencing on the date of the
      Meeting until the annual general meeting of shareholders to be held in 2025.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Each of Mr. Moshe Mizrahy and Dr. Michael Kreindel has consented to being named in this Proxy Statement and has informed us that he is willing to continue serving as a director if
      re-elected.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In accordance with the Companies Law, each of Mr. Moshe Mizrahy and Dr. Michael Kreindel has certified to us that he satisfies all of the requirements of the Companies Law to serve
      as a director of a public company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If re-elected pursuant to this proposal, each of Mr. Moshe Mizrahy and Dr. Michael Kreindel will continue to be party to an indemnification agreement and exculpation agreement with
      the Company in the form of indemnification letter and exculpation letter which were entered into in connection with the consummation of our initial public offering and listing on the Nasdaq Stock Market. Each of Mr. Moshe Mizrahy and Dr. Michael
      Kreindel will also continue to be insured under the Company&#8217;s directors&#8217; and officers&#8217; insurance coverage policy in effect from time to time, which provides coverage for all directors and other officers of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In addition, if re-elected pursuant to this proposal, each of Mr. Moshe Mizrahy and Dr. Michael Kreindel will continue to receive cash participation compensation and annual
      compensation in accordance with the Israeli Companies Law Regulations (Reliefs to Public Companies which Shares are Traded on an Exchange Outside of Israel), 5760-2000, with reference to the Israeli Companies Law Regulations (Rules concerning
      Compensation and Expenses of an External Director), 5760-2000, and in accordance with our Compensation Policy.&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At the Meeting, the shareholders will be asked to re-elect each of Mr. Moshe Mizrahy and Dr. Michael Kreindel to serve as a Class III director of the Company,&#160;and to hold office
      until the annual general meeting of shareholders to be held in 2025. If re-elected, and as approved by our board of directors, Mr. Moshe Mizrahy is expected to continue serving as the chairman of our board of directors.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Set forth below is information about the nominees, Mr. Moshe Mizrahy and Dr. Michael Kreindel, including age, positions held, principal occupation, business history and experience
      as director:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Moshe Mizrahy </font><font style="font-style: italic;">(Age 69).</font> Moshe Mizrahy co-founded the Company in 2008 and has
      been our Chief Executive Officer and Chairman of the board of directors since inception. Prior to that, Mr. Mizrahy was co-founder and chief executive officer of Syneron Medical Ltd., a medical aesthetic device company based in Israel. Mr. Mizrahy
      was also the former chief executive officer of Home Skinovations Ltd., an international medical aesthetic consumer devices company active in the home use market, and is currently the chairman of its board since 2007. In addition to Home Skinovations
      Ltd., Mr. Mizrahy currently sits on the board of directors of the following companies: SipNose Ltd., Pet Novations Ltd., Peri-Ness Technologies Ltd., O.B. - Tools Ltd., Urifer Ltd., Easy Notes Ltd., Escape Rescue Systems Ltd., New Forest Wood
      Products (2012) Ltd., Med Smart Hub Ltd., Ivy Diagnostics (2021) Ltd., M.N. Business Strategy Ltd., Himalaya Family Office Advising Ltd., and Polimer Logistics (Israel) Ltd. Mr. Mizrahy has a B.S. in Engineering from the Tel Aviv University and an
      MBA from Pace University, New York.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">Dr. Michael Kreindel</font><font style="font-style: italic;"> (Age 55).</font><font style="font-weight: bold; font-style: italic;">&#160;</font>Dr. Michael Kreindel co-founded the Company in 2008 and has served as our Chief Technology Officer since inception. Dr. Kreindel became a director for the Company in August 2019. He previously was a co-founder of, and served as CTO
      of, Syneron Medical Ltd. from 2001 to 2007. Dr. Kreindel has a Ph.D. in physics and mathematics, and also graduated as an engineer and physicist in experimental and theoretical nuclear physics from Ural Politechnical Institute, Russia.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"></div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>Proposed&#160;Resolutions</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We are therefore proposing to adopt the following resolutions:</div>
    <div style="line-height: 1.25;"></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font>,&#160;to re-elect Mr. Moshe Mizrahy to serve as a Class III director of the Company, and to hold office until the annual general
      meeting of shareholders to be held in 2025&#160;and until his successor is duly elected and qualified, or until his earlier resignation or retirement&#8221;.</div>
    <div style="line-height: 1.25"><br>
    </div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font>,&#160;to re-elect Dr. Michael Kreindel to serve as a Class III director of the Company, and to hold office until the annual general
      meeting of shareholders to be held in 2025&#160;and until his successor is duly elected and qualified, or until his earlier resignation or retirement&#8221;.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;"><u>Required Vote</u></div>
    <div style="line-height: 1.25"><br>
    </div>
    <div style="text-indent: 36pt; line-height: 1.25;">See &#8220;Quorum and Required Vote&#8221; above.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>Board Recommendation</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-weight: bold;">The Board unanimously recommends that you vote &#8220;FOR&#8221; the proposed resolutions.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL TWO</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">INCREASE IN THE COMPANY&#8217;S SHARE CAPITAL AND CORRESPONDING AMENDMENT TO</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">ARTICLE 5 OF THE COMPANY&#8217;S ARTICLES OF ASSOCIATION</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 39.6pt; line-height: 1.25;">Our Company's authorized share capital is currently NIS 1,000,000, consisting of 100,000,000 Ordinary Shares, par value NIS 0.01 per share. As of December 31, 2021, we had
      approximately 11,263,350 authorized ordinary shares remaining available for future issuance, which number excludes a share reserve issuable under our 2018 Incentive Plan free pool of shares and outstanding options and RSUs, whether vested or not,
      under the Company's incentive plans.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 39.6pt; line-height: 1.25;">Under the Companies Law, a company may not issue shares in excess of its registered share capital.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 39.6pt; line-height: 1.25;">The Board believes that the amount of remaining available share capital does not provide our Company with sufficient flexibility for future financial and capital requirements and
      needs as they arise, or for our pursuit of other business opportunities<font style="font-weight: bold;">&#160;</font>and other bona fide corporate purposes. In order to take proper advantage of propitious market conditions or to pursue such other
      opportunities, our Board recommends that we increase the number of Ordinary Shares that we are authorized to issue by 400,000,000 from 100,000,000 Ordinary Shares to 500,000,000 Ordinary Shares, and correspondingly increase the authorized share
      capital of our Company from NIS 1,000,000 to NIS 5,000,000, which increase shall be effected via the adoption of an amendment to Article 5 of our Articles of Association, which sets forth our Company's authorized share capital.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 39.6pt; line-height: 1.25;">In addition to potential issuance in equity financings, acquisitions or other potential transactions, the additional Ordinary Shares would also be available for us for share
      dividends or splits should our Board decide that, in light of market conditions then prevailing, such measures would broaden the public ownership of, and enhance the market for, our Ordinary Shares. The additional shares would generally be available
      for issuance for these and other purposes at the discretion of the Board without, in most cases, the delays and expenses attendant to obtaining further shareholders' approval. To the extent required by the Companies Law or the NASDAQ Listing Rules,
      we would, nevertheless, solicit shareholders' approval in the event that we propose to issue Ordinary Shares in connection with a merger, significant acquisition or significant private placement.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 39.6pt; line-height: 1.25;">Adoption of an amendment to our Articles of Association would not have any immediate dilutive effect on the proportionate voting power or other rights of our existing
      shareholders.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;Therefore, we propose to increase the Company&#8217;s authorized share capital from NIS 1,000,000 consisting of 100,000,000 ordinary shares of a nominal value of NIS 0.01 each, to NIS
      5,000,000 consisting of 500,000,000 ordinary shares of nominal value NIS 0.01 each.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 39.6pt; line-height: 1.25;">If the above proposed increase in the Company&#8217;s authorized share capital is approved by the shareholders of the Company, then Article 5 of the Articles of Association of the
      Company shall be amended effective as of the date of the Meeting to read as follows:</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 39.6pt; line-height: 1.25;">&#8220;The authorized share capital of the Company shall consist of NIS 5,000,000 divided into 500,000,000 Ordinary Shares, of a nominal value of NIS 0.01 each (the &#8220;Shares&#8221;). </div>
    <div style="text-align: justify; text-indent: 39.6pt; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 39.6pt; line-height: 1.25;">The Shares shall rank pari passu in all respects. The Shares may be redeemable to the extent set forth in Article 13.&#8221;</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;"><u>Proposed Resolutions</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We are therefore proposing to adopt the following resolution:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font>,&#160;that the Company&#8217;s authorized share capital be increased from NIS 1,000,000 divided into 100,000,000 Ordinary Shares of a nominal
      value of NIS 0.01 each to NIS 5,000,000 divided into 500,000,000 Ordinary Shares of a nominal value of NIS 0.01 each, and that Article 5 of the Company&#8217;s Articles of Association be amended accordingly.&#8221;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;"><u>Required Vote</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">See &#8220;Quorum and Required Vote&#8221; above.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>Board Recommendation</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25; font-weight: bold;">The Board unanimously recommends that you vote &#8220;FOR&#8221; the proposed resolutions.</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL THREE</div>
    <div style="line-height: 1.25"><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">RE-APPOINTMENT OF AUDITORS</div>
    <div style="line-height: 1.25; font-weight: bold;"><u>Background</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Kesselman &amp; Kesselman Certified Public Accounts, a member of PWC, (&#8220;<font style="font-weight: bold;">PwC</font>&#8221;), currently serves as our independent registered public
      accounting firm and audited our financial statements for the year ended December 31, 2021. PwC has served as our auditors since our inception in 2008. PwC does not have and has not had any financial interest, direct or indirect, in our Company, and
      does not have and has not had any connection with our Company except in its professional capacity as our independent auditors.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our audit committee and board of directors have authorized and approved the appointment of PwC as the Company's independent registered public accounting firm for the year ending
      December 31, 2022, and until the next annual general meeting. Our audit committee and board of directors believe that the appointment of PwC as the independent public accountants of the Company is appropriate and in the best interest of the Company
      and its shareholders.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under the Companies Law and our articles of association, the shareholders of the Company are authorized to appoint the Company&#8217;s independent auditors.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Our Audit Committee, in accordance with our charter, reviews and pre-approves all audit services and permitted non-audit services (including the fees and other terms) to be
      provided to our independent auditors.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">At the Meeting, shareholders will be asked to approve the re-appointment of PwC, as the Company&#8217;s independent auditors for the year ending December 31, 2022, and its service until
      the annual general meeting of shareholders to be held in 2023.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">Information on fees paid to the Company's independent public accountants may be found in Item 16C of the Annual Report on Form 20-F for the year ended December 31, 2021, which was filed with the SEC on
      February 10, 2022.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;"><u>Proposed Resolutions</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We are therefore proposing to adopt the following resolution:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font>,&#160;to approve the re-appointment of Kesselman &amp; Kesselman Certified Public Accounts, a member of PWC, as the Company&#8217;s
      independent auditors for the fiscal year ending December 31, 2022, and its service until the annual general meeting of shareholders to be held in 2023.&#8221;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;"><u>Required Vote</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">See &#8220;Quorum and Required Vote&#8221; above.</div>
    <br>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>Board Recommendation</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 35.45pt; line-height: 1.25; font-weight: bold;">The Board unanimously recommends that you vote &#8220;FOR&#8221; the proposed resolution.</div>
    <div style="text-indent: 35.45pt; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">12</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROPOSAL FOUR</div>
    <div style="line-height: 1.25"><br>
    </div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">APPROVAL OF</font>&#160;<font style="font-weight: bold;">THE GRANT OF RESTRICTED SHARE UNITS</font></div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">TO DR. MICHAEL ANGHEL, MR. BRUCE MANN AND DR. HADAR RON</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;"><u>Background</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Under Israeli law, any arrangement between a public company and its Directors as to the terms of service require the approval of the compensation committee, board of directors and
      holders of a majority of the voting power represented at the general meeting in person or by proxy or written ballot and voting thereon.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Proposed grant is in compliance with the Company&#8217;s Compensation Policy, as amended.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Following the approval of our compensation committee, our Board has approved to grant to each of the following non-executive directors: Dr. Michael Anghel, Mr. Bruce Mann and Dr.
      Hadar Ron, 2,000 restricted share units under the Company's 2018 Incentive Plan totaling 6,000 restricted share units, half of which shall vest on December 31, 2022, and the remaining half shall vest on December 31, 2023, subject to their continued
      services on the date of vesting.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25; font-weight: bold;"><u>Proposed Resolutions</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">We are therefore proposing to adopt the following resolution:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#8220;<font style="font-weight: bold;">RESOLVED</font>,&#160;to approve and ratify the grant to each of the following Directors of the Company: Dr. Michael Anghel, Mr. Bruce Mann and Dr.
      Hadar Ron, 2,000 restricted share units under the Company's 2018 Incentive Plan totaling 6,000 restricted share units, half of which shall vest on December 31, 2022, and the remaining half shall vest on December 31, 2023, subject to their continued
      services on the date of vesting.&#8221;</div>
    <div style="line-height: 1.25"><br>
    </div>
    <div style="line-height: 1.25; font-weight: bold;"><u>Required Vote</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 36pt; line-height: 1.25;">See &#8220;Quorum and Required Vote&#8221; above.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>Board Recommendation</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-indent: 35.45pt; line-height: 1.25; font-weight: bold;">The Board unanimously recommends that you vote &#8220;FOR&#8221; the proposed resolution.</div>
    <div style="text-indent: 35.45pt; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" id="DSPFPageNumber">13</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">OTHER BUSINESS</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">The Board is not aware of any other matters that may be presented at the Meeting other than those specified in the enclosed&#160;Notice of Annual General Meeting of Shareholders. If any
      other matters do properly come before the Meeting, it is intended that the persons named as proxies will vote, pursuant to their discretionary authority, according to their best judgment and in the interest of the Company.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">ADDITIONAL INFORMATION</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 35.45pt; line-height: 1.25;">The Company&#8217;s&#160;annual report on Form 20-F for the year ended December 31, 2021, which was filed with the SEC on February 10, 2022, and other filings with the SEC,&#160;are available
      for viewing and downloading on the SEC&#8217;s website at&#160;<font style="font-style: italic;"><u>www.sec.gov</u>&#160;</font>as well as under the Investors section of the Company&#8217;s website at&#160;<font style="font-style: italic;"><u>www.inmodemd.com</u>.&#160;</font>Shareholders






      may obtain a copy of these documents without charge at&#160;<font style="font-style: italic;"><u>www.inmodemd.com</u></font>.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; text-indent: 15pt; line-height: 1.25;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company is subject to the information reporting requirements of the Exchange Act, as amended, applicable to foreign private issuers. The Company fulfills these
      requirements by filing reports with the SEC. The Company&#8217;s SEC filings are available to the public on the SEC&#8217;s website at&#160;<font style="font-style: italic;"><u>www.sec.gov</u>.</font>&#160;As a foreign private issuer, the Company is exempt from the rules
      under the Exchange Act related to the furnishing and content of proxy statements. The circulation of this Proxy Statement should not be taken as an admission that the Company is subject to those rules.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" align="right" style="width: 50%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z888708bc39db4b9a94996cf4d7fb7a1f">

        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">BY ORDER OF THE BOARD OF DIRECTORS</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: justify; line-height: 1.25;">/s/ Moshe Mizrahy</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">Moshe Mizrahy</div>
          </td>
        </tr>
        <tr>
          <td style="width: 100%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25;">CEO and Chairman of the Board of Directors</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; clear: both;">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">February 10, 2022</div>
      <div style="line-height: 1.25;"> <br>
      </div>
      <div style="line-height: 1.25; text-align: center;">14<br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; text-align: center;">
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">INMODE LTD</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br>
        </div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Proxy for Annual General Meeting of the Shareholders on April 4, 2022</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Solicited on Behalf of the Board of Directors</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
        </div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">(Continued and to be signed on the reverse side)</div>
        <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
        </div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: left;">&#160; &#160;
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 12pt"><b>ANNUAL GENERAL MEETING OF SHAREHOLDERS OF</b></font></p>
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-size: 24pt"><b>INMODE LTD</b></font></p>
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0; text-align: center"><font style="font-size: 12pt"><b>April 4, 2022</b></font></p>
          <table cellspacing="0" cellpadding="0" align="CENTER" style="font: 10pt Times New Roman, Times, Serif; width: 40%; border-collapse: collapse; background-color: rgb(170,163,162)">

              <tr style="vertical-align: top">
                <td style="width: 40%; border: Black 1pt solid; font-size: 10pt; text-align: center; padding-top: 6pt; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>PROXY VOTING INSTRUCTIONS</b></font></td>
              </tr>

          </table>
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
          <div style="POSITION:RELATIVE;FLOAT:LEFT;WIDTH:53%">
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><u>INTERNET</u> - </b>Access &#8220;<b>www.voteproxy.com</b>&#8221; and follow the on-screen instructions or scan the QR code with your smartphone. Have your proxy
              card available when you access the web page.</p>
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><u>TELEPHONE</u> - </b>Call toll-free <b>1-800-PROXIES </b>(1-800-776-9437) in the United States or <b>1-718-921-8500 </b>from foreign countries
              from any touch-tone telephone and follow the instructions. Have your proxy card available when you call.</p>
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Vote online/phone until 11:59 PM EST the day before the meeting.</p>
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><u>MAIL</u> - </b>Sign, date and mail your proxy card in the envelope provided as soon as possible.</p>
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><u>IN PERSON</u> - </b>You may vote your shares in person by attending the Annual General Meeting.</p>
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><u>GO GREEN</u> - </b>e-Consent makes it easy to go paperless. With e-Consent, you can quickly access your proxy material, statements and other eligible
              documents online, while reducing costs, clutter and paper waste. Enroll today via www.astfinancial.com to enjoy online access.</p>
          </div>
          <div style="POSITION:RELATIVE;FLOAT:RIGHT;WIDTH:43%">
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><img src="ex992101_v1.jpg" alt=""></p>
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
            <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
            <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                <tr>
                  <td style="width: 50%; border: Black 1pt solid; font-size: 10pt; text-align: center; padding-top: 6pt; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>COMPANY NUMBER</b></font></td>
                  <td style="vertical-align: top; width: 50%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; padding-top: 6pt; padding-bottom: 6pt"><font style="font-size: 12pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; text-align: center; padding-top: 6pt; padding-bottom: 6pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>ACCOUNT NUMBER</b></font></td>
                  <td style="vertical-align: top; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; padding-top: 6pt; padding-bottom: 6pt"><font style="font-size: 12pt">&#160;</font></td>
                </tr>
                <tr style="vertical-align: top">
                  <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; background-color: rgb(199,200,202); padding-top: 6pt; padding-bottom: 6pt"><font style="font-size: 12pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; padding-top: 6pt; padding-bottom: 6pt"><font style="font-size: 12pt">&#160;</font></td>
                </tr>

            </table>
          </div>
          <br clear="ALL">
          <br>
          <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

              <tr style="vertical-align: top">
                <td colspan="3" style="border: Black 1pt solid">
                  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><u>NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS</u></b>:</p>
                  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Notice of Meeting, Proxy Statement and Proxy Card</p>
                  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">are available at https://astproxyportal.com/ast/22993</p>
                </td>
              </tr>
              <tr style="vertical-align: top">
                <td style="width: 15%; text-align: right"><font style="font-size: 8pt"><img src="ex992102_v1.jpg" alt="">&#160;&#160;</font></td>
                <td style="width: 70%; text-align: center; vertical-align: bottom; font-size: 10pt;">Please detach along perforated line and mail in the envelope provided <u>IF</u> you are not voting via telephone or the Internet.</td>
                <td style="width: 15%"><font style="font-size: 8pt">&#160;&#160;<img src="ex992102_v1.jpg" alt=""></font></td>
              </tr>

          </table>
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
          <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

              <tr style="vertical-align: top">
                <td style="width: 5%; font-size: 10pt"><font style="font-size: 12pt"><img src="ex992103_v1.jpg" alt=""></font></td>
                <td style="width: 60%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt">00030030030030030000&#160;&#160;&#160;&#160;&#160;6</font></td>
                <td style="width: 35%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt">040422</font></td>
              </tr>

          </table>
          <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>
          <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

              <tr style="vertical-align: top">
                <td style="border: Black 1pt solid">
                  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE BOARD RECOMMENDS THAT THE SHAREHOLDERS VOTE FOR EACH OF THE PROPOSALS.</b></p>
                  <font style="font-size: 10pt;"> </font>
                  <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman,Times,serif;"><b>PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN
                        BLUE OR BLACK INK AS SHOWN HERE&#160;&#9746;</b></font></p>
                </td>
              </tr>

          </table>
          <div style="POSITION:RELATIVE;FLOAT:LEFT;WIDTH:49%">
            <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                <tr>
                  <td style="vertical-align: top; width: 90%; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="width: 10%; border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify">&#160;</td>
                  <td style="border-right: Black 1pt solid; text-align: center">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify">&#160;</td>
                  <td style="border-right: Black 1pt solid; text-align: center">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify">&#160;</td>
                  <td style="border-right: Black 1pt solid; text-align: center">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify">&#160;</td>
                  <td style="border-right: Black 1pt solid; text-align: center">&#160;</td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                </tr>
                <tr>
                  <td style="vertical-align: top; border-bottom: 1pt solid Black; text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">To change the address on your account, please check the box at right and
                      indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via this method.</font></td>
                  <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><img src="ex992104_v1.jpg" alt=""></td>
                </tr>

            </table>
          </div>
          <div style="POSITION:RELATIVE;FLOAT:RIGHT;WIDTH:50%">
            <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                <tr style="vertical-align: top">
                  <td><font style="font-size: 4pt">&#160;</font></td>
                  <td><font style="font-size: 4pt">&#160;</font></td>
                  <td style="text-align: center"><font style="font-size: 4pt">&#160;</font></td>
                  <td style="text-align: center"><font style="font-size: 4pt">&#160;</font></td>
                  <td style="text-align: center"><font style="font-size: 4pt">&#160;</font></td>
                </tr>
                <tr style="vertical-align: top">
                  <td style="width: 5%"><font style="font-size: 7pt">&#160;</font></td>
                  <td style="width: 71%"><font style="font-size: 7pt">&#160;</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">FOR</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;AGAINST&#160;</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">ABSTAIN</font></td>
                </tr>
                <tr style="vertical-align: top">
                  <td style="font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">1a.</font></td>
                  <td style="text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">To re-elect Mr. Moshe Mizrahy to serve as a Class III director of the Company, and to hold office until the annual general meeting
                      of shareholders to be held in 2025 and until his successor is duly elected and qualified, or until his earlier resignation or retirement.</font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                </tr>

            </table>
            <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
            <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                <tr style="vertical-align: top">
                  <td style="width: 5%"><font style="font-size: 7pt">&#160;</font></td>
                  <td style="width: 71%"><font style="font-size: 7pt">&#160;</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">FOR</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;AGAINST&#160;</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">ABSTAIN</font></td>
                </tr>
                <tr style="vertical-align: top">
                  <td style="font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">1b.</font></td>
                  <td style="text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">To re-elect Dr. Michael Kreindel to serve as a Class III director of the Company, and to hold office until the annual general
                      meeting of shareholders to be held in 2025 and until his successor is duly elected and qualified, or until his earlier resignation or retirement.</font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                </tr>

            </table>
            <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
            <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                <tr style="vertical-align: top">
                  <td style="width: 5%"><font style="font-size: 7pt">&#160;</font></td>
                  <td style="width: 71%"><font style="font-size: 7pt">&#160;</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">FOR</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;AGAINST&#160;</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">ABSTAIN</font></td>
                </tr>
                <tr style="vertical-align: top">
                  <td style="font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">2.</font></td>
                  <td style="text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">That the Company&#8217;s authorized share capital be increased from NIS 1,000,000 divided into 100,000,000 Ordinary Shares of a nominal
                      value of NIS 0.01 each to NIS 5,000,000 divided into 500,000,000 Ordinary Shares of a nominal value of NIS 0.01 each, and that Article 5 of the Company&#8217;s Articles of Association be amended accordingly.</font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                </tr>

            </table>
            <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
            <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                <tr style="vertical-align: top">
                  <td style="width: 5%"><font style="font-size: 7pt">&#160;</font></td>
                  <td style="width: 71%"><font style="font-size: 7pt">&#160;</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">FOR</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;AGAINST&#160;</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">ABSTAIN</font></td>
                </tr>
                <tr style="vertical-align: top">
                  <td style="font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">3.</font></td>
                  <td style="text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">To approve the re-appointment of Kesselman &amp; Kesselman Certified Public Accounts, a member of PWC, as the Company&#8217;s independent
                      auditors for the fiscal year ending December 31, 2022, and its service until the annual general meeting of shareholders to be held in 2023.</font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                </tr>

            </table>
            <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
            <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                <tr style="vertical-align: top">
                  <td style="width: 5%"><font style="font-size: 7pt">&#160;</font></td>
                  <td style="width: 71%"><font style="font-size: 7pt">&#160;</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">FOR</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;AGAINST&#160;</font></td>
                  <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">ABSTAIN</font></td>
                </tr>
                <tr style="vertical-align: top">
                  <td style="font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">4.</font></td>
                  <td style="text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">To approve and ratify the grant to each of the following Directors of the Company: Dr. Michael Anghel, Mr. Bruce Mann and Dr. Hadar
                      Ron, 2,000 restricted share units under the Company's 2018 Incentive Plan totaling 6,000 restricted share units, half of which shall vest on December 31, 2022, and the remaining half shall vest on December 31, 2023, subject to their
                      continued services on the date of vesting.</font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                </tr>

            </table>
          </div>
          <br clear="ALL">
          <p style="margin-top: 0; margin-bottom: 0; font: 2pt Times New Roman, Times, Serif">&#160;</p>
          <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

              <tr style="vertical-align: top">
                <td style="width: 17%; border-right: 1pt solid Black; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">Signature of Shareholder&#160;</font></td>
                <td style="width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
                <td style="width: 5%; border-right: 1pt solid Black; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;Date:</font></td>
                <td style="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
                <td style="width: 17%; border-right: 1pt solid Black; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;Signature of Shareholder&#160;</font></td>
                <td style="width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
                <td style="width: 5%; border-right: 1pt solid Black; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;Date:</font></td>
                <td style="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
              </tr>

          </table>
          <div> <br>
          </div>
          <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

              <tr>
                <td style="vertical-align: bottom; width: 5%"><img src="ex992103_v1.jpg" alt=""></td>
                <td style="vertical-align: top; width: 6%; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;"><b>Note:</b></font></td>
                <td style="vertical-align: top; width: 84%; text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each
                    holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as
                    such. If signer is a partnership, please sign in partnership name by authorized person.</font></td>
                <td style="vertical-align: bottom; width: 5%; text-align: right"><font style="font-size: 8pt"><img src="ex992103_v1.jpg" alt=""></font></td>
              </tr>

          </table>
        </div>
        <div><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
          <div style="page-break-after: always;" id="DSPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <br>
        <div>
          <div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">ANNUAL GENERAL MEETING OF SHAREHOLDERS OF</div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> &#160; </div>
          </div>
          <div style="line-height: 1.25">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">INMODE LTD</div>
          </div>
          <div style="line-height: 1.25">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
            </div>
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">April 4, 2022</div>
          </div>
          <div style="line-height: 1.25">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><br>
            </div>
          </div>
          <div style="line-height: 1.25">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

                <tr>
                  <td style="width: 33%;" colspan="1">&#160;</td>
                  <td style="width: 33%;">
                    <div>
                      <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
                        <div style="line-height: 1.25">
                          <div style="text-align: center; line-height: 1.25; font-weight: bold;">GO GREEN</div>
                        </div>
                      </div>
                      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">e-Consent makes it easy to go paperless. With e-Consent, you can quickly access your proxy material, statements and other eligible
                        documents online, while reducing costs, clutter and paper waste. Enroll today via www.astfinancial.com to enjoy online access.</div>
                    </div>
                  </td>
                  <td style="width: 33%;" colspan="1">&#160;</td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25"><font style="font-family: 'Times New Roman',Times,serif;"><br>
            </font>
            <div>
              <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u><font style="font-weight: bold;">NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS</font>:</u></div>
            </div>
            <div style="font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">The Notice of Meeting, Proxy Statement and Proxy Card</div>
            </div>
            <div style="font-family: 'Times New Roman',Times,serif;">
              <div style="line-height: 1.25;">are available at https://astproxyportal.com/ast/22993</div>
            </div>
            <div><font style="font-family: 'Times New Roman',Times,serif;"><br>
              </font>
              <div style="font-family: 'Times New Roman',Times,serif;">
                <div style="line-height: 1.25; font-size: 12pt;">Please sign, date and mail</div>
                <div style="line-height: 1.25; font-size: 12pt;">your proxy card in the</div>
                <div style="line-height: 1.25; font-size: 12pt;">envelope provided as soon</div>
                <div style="line-height: 1.25; font-size: 12pt;">as possible.</div>
              </div>
              <div><br>
                <div style="font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#8595; Please detach along perforated line and mail in the envelope provided. &#8595;</div>
                </div>
                <div> <br>
                </div>
                <div>
                  <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                      <tr style="vertical-align: top">
                        <td style="width: 5%; font-size: 10pt"><font style="font-size: 12pt"><img src="ex992103_v1.jpg" alt=""></font></td>
                        <td style="width: 60%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt">00030030030030030000&#160;&#160;&#160;&#160;&#160;6</font></td>
                        <td style="width: 35%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt">040422</font></td>
                      </tr>

                  </table>
                  <br>
                </div>
              </div>
            </div>
          </div>
        </div>
        <div>
          <div style="text-align: left;">
            <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                <tr style="vertical-align: top">
                  <td style="border: Black 1pt solid">
                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE BOARD RECOMMENDS THAT THE SHAREHOLDERS VOTE FOR EACH OF THE PROPOSALS.</b></p>
                    <font style="font-size: 10pt;"> </font>
                    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="font-family: Times New Roman,Times,serif;"><b>PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN
                          BLUE OR BLACK INK AS SHOWN HERE&#160;&#9746;</b></font></p>
                  </td>
                </tr>

            </table>
            <div style="POSITION:RELATIVE;FLOAT:LEFT;WIDTH:49%">
              <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                  <tr>
                    <td style="vertical-align: top; width: 90%; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="width: 10%; border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify">&#160;</td>
                    <td style="border-right: Black 1pt solid; text-align: center">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify">&#160;</td>
                    <td style="border-right: Black 1pt solid; text-align: center">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify">&#160;</td>
                    <td style="border-right: Black 1pt solid; text-align: center">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify">&#160;</td>
                    <td style="border-right: Black 1pt solid; text-align: center">&#160;</td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; border-bottom: Black 1pt solid; text-align: justify"><font style="font-size: 8pt">&#160;</font></td>
                    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 8pt">&#160;</font></td>
                  </tr>
                  <tr>
                    <td style="vertical-align: top; border-bottom: 1pt solid Black; text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">To change the address on your account, please check the box at right and
                        indicate your new address in the address space above. Please note that changes to the registered name(s) on the account may not be submitted via this method.</font></td>
                    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><img src="ex992104_v1.jpg" alt=""></td>
                  </tr>

              </table>
            </div>
            <div style="POSITION:RELATIVE;FLOAT:RIGHT;WIDTH:50%">
              <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                  <tr style="vertical-align: top">
                    <td><font style="font-size: 4pt">&#160;</font></td>
                    <td><font style="font-size: 4pt">&#160;</font></td>
                    <td style="text-align: center"><font style="font-size: 4pt">&#160;</font></td>
                    <td style="text-align: center"><font style="font-size: 4pt">&#160;</font></td>
                    <td style="text-align: center"><font style="font-size: 4pt">&#160;</font></td>
                  </tr>
                  <tr style="vertical-align: top">
                    <td style="width: 5%"><font style="font-size: 7pt">&#160;</font></td>
                    <td style="width: 71%"><font style="font-size: 7pt">&#160;</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">FOR</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;AGAINST&#160;</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">ABSTAIN</font></td>
                  </tr>
                  <tr style="vertical-align: top">
                    <td style="font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">1a.</font></td>
                    <td style="text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">To re-elect Mr. Moshe Mizrahy to serve as a Class III director of the Company, and to hold office until the annual general meeting
                        of shareholders to be held in 2025 and until his successor is duly elected and qualified, or until his earlier resignation or retirement.</font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  </tr>

              </table>
              <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
              <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                  <tr style="vertical-align: top">
                    <td style="width: 5%"><font style="font-size: 7pt">&#160;</font></td>
                    <td style="width: 71%"><font style="font-size: 7pt">&#160;</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">FOR</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;AGAINST&#160;</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">ABSTAIN</font></td>
                  </tr>
                  <tr style="vertical-align: top">
                    <td style="font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">1b.</font></td>
                    <td style="text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">To re-elect Dr. Michael Kreindel to serve as a Class III director of the Company, and to hold office until the annual general
                        meeting of shareholders to be held in 2025 and until his successor is duly elected and qualified, or until his earlier resignation or retirement.</font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  </tr>

              </table>
              <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
              <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                  <tr style="vertical-align: top">
                    <td style="width: 5%"><font style="font-size: 7pt">&#160;</font></td>
                    <td style="width: 71%"><font style="font-size: 7pt">&#160;</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">FOR</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;AGAINST&#160;</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">ABSTAIN</font></td>
                  </tr>
                  <tr style="vertical-align: top">
                    <td style="font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">2.</font></td>
                    <td style="text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">That the Company&#8217;s authorized share capital be increased from NIS 1,000,000 divided into 100,000,000 Ordinary Shares of a nominal
                        value of NIS 0.01 each to NIS 5,000,000 divided into 500,000,000 Ordinary Shares of a nominal value of NIS 0.01 each, and that Article 5 of the Company&#8217;s Articles of Association be amended accordingly.</font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  </tr>

              </table>
              <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
              <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                  <tr style="vertical-align: top">
                    <td style="width: 5%"><font style="font-size: 7pt">&#160;</font></td>
                    <td style="width: 71%"><font style="font-size: 7pt">&#160;</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">FOR</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;AGAINST&#160;</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">ABSTAIN</font></td>
                  </tr>
                  <tr style="vertical-align: top">
                    <td style="font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">3.</font></td>
                    <td style="text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">To approve the re-appointment of Kesselman &amp; Kesselman Certified Public Accounts, a member of PWC, as the Company&#8217;s
                        independent auditors for the fiscal year ending December 31, 2022, and its service until the annual general meeting of shareholders to be held in 2023.</font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  </tr>

              </table>
              <p style="margin-top: 0; margin-bottom: 0">&#160;</p>
              <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                  <tr style="vertical-align: top">
                    <td style="width: 5%"><font style="font-size: 7pt">&#160;</font></td>
                    <td style="width: 71%"><font style="font-size: 7pt">&#160;</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">FOR</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;AGAINST&#160;</font></td>
                    <td style="width: 8%; text-align: center; font-size: 9pt;"><font style="font-family: Times New Roman,Times,serif;">ABSTAIN</font></td>
                  </tr>
                  <tr style="vertical-align: top">
                    <td style="font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">4.</font></td>
                    <td style="text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">To approve and ratify the grant to each of the following Directors of the Company: Dr. Michael Anghel, Mr. Bruce Mann and Dr.
                        Hadar Ron, 2,000 restricted share units under the Company's 2018 Incentive Plan totaling 6,000 restricted share units, half of which shall vest on December 31, 2022, and the remaining half shall vest on December 31, 2023, subject to
                        their continued services on the date of vesting.</font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                    <td style="text-align: center"><font style="font-size: 7pt"><img src="ex992104_v1.jpg" alt=""></font></td>
                  </tr>

              </table>
            </div>
            <br clear="ALL">
            <p style="margin-top: 0; margin-bottom: 0; font: 2pt Times New Roman, Times, Serif">&#160;</p>
            <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                <tr style="vertical-align: top">
                  <td style="width: 17%; border-right: 1pt solid Black; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">Signature of Shareholder&#160;</font></td>
                  <td style="width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="width: 5%; border-right: 1pt solid Black; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;Date:</font></td>
                  <td style="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="width: 17%; border-right: 1pt solid Black; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;Signature of Shareholder&#160;</font></td>
                  <td style="width: 18%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
                  <td style="width: 5%; border-right: 1pt solid Black; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">&#160;Date:</font></td>
                  <td style="width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><font style="font-size: 8pt">&#160;</font></td>
                </tr>

            </table>
            <div> <br>
            </div>
            <table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

                <tr>
                  <td style="vertical-align: bottom; width: 5%"><img src="ex992103_v1.jpg" alt=""></td>
                  <td style="vertical-align: top; width: 6%; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;"><b>Note:</b></font></td>
                  <td style="vertical-align: top; width: 84%; text-align: justify; font-size: 10pt;"><font style="font-family: Times New Roman,Times,serif;">Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each
                      holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title
                      as such. If signer is a partnership, please sign in partnership name by authorized person.</font></td>
                  <td style="vertical-align: bottom; width: 5%; text-align: right"><font style="font-size: 8pt"><img src="ex992103_v1.jpg" alt=""></font></td>
                </tr>

            </table>
          </div>
          <div><br>
          </div>
        </div>
      </div>
    </div>
    <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25"><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex992101_v1.jpg
<TEXT>
begin 644 ex992101_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 0@!" P$1  (1 0,1 ?_$ *<   (# 0 #
M      @)!@<*!0 #"P$  P$!                  $" P00   & @$" @0)
M!P@+ 0    $" P0%!@<("0 1$A,A%#0U,6$B,Q46-C<*05$R8A<X&8&A0E(C
M8U15\%-$9)97&%C8.5D:$0 ! P$$" 4$ P$        ! !$"(3%A$@/P05%Q
M@9'1,J&QP2(3X4)B,_%2(W+_V@ , P$  A$#$0 _ &:[%CN=L/RDYNU,UDRU
MK=@*JXOUXJ.?IVR90U[@<CN)E6;:T8MC4?R8+L) SY>7MRKLZZISAY91 ?3Z
M1QEW, %UPD!EB4B='Z*O?V";PBZ!D'+1QI^MBN#8&_\ TG07F"X%0$@1\/T[
M^F*@]NWY^DQ_%5CC^?((>\U7CD*T6WXT&U^S;FK5//\ 1=H\CXR;RYJ;J_6:
MD@%/L^0"5J1;$=/'4@X.X>1[54R2R?8I?-*/I[" C$%B C%&47B9:[K!<M$T
MU?:Q/W;=3#E6TPK=;FM>,%?7K'.5I"E5Z5KF3KA.5>XNXR'@H$M28_V\%+P+
M;S2$?.1<>LE+V3]'BLLY %@647]I,BQ->:R;:Y?B%LL8)=+Z_P"W/%LGG[86
M5LDQ)5I:!B*?B.2>U-=\HWAF;.EK8HMCQX!"I?)6%8IC]^WA] ",/<"MC!QB
MQ$!,/Y?]E=@L9[[Z-ZDZG1^"L(M-H:U+K2DA;L&U*Y&@9ANQ9R*)WJ!VT:X<
M)HE!1(Q"&3'N;O\ D["R:L&9E.76!))H5/;KJGR%XXG5JQ?.4GCFJ=B;)(K.
M8:;U%A64@@FX("B)U6ZD[XR%4(/<._PATF-R>.!J,;;@APW$I7)AJIISD[<R
M#WCT;SG2,9#!$=P]%U*KS565<3=KA*H5LWEW4JZ:-U&KB:*J<#)F$2)B !W'
MOT,6>C(QQ)P^Y^"!#^+%M;_E> _N!^O/W%T?W_\ XKV+X?B_1^+I]%#RVFW:
MGI-4%G7-%R7M6Z*KA=SQ.^0@W03.JNNLM7L5)IHHI)@91554Y@*4I0$QA'L'
MIZ#W\#Z)#](_Z'F5\X!E@+/W[=63HV%<P U#*[1<SD<;W0&X-PMR9Q6%88;R
MP1!(/%XN_A\/I^#J:<5U.,+7+=%RMH*M>1O@);+HJMUV['5U%9!=,Z*R*J60
M_ HDJDH4JB:B9BB!BF ! 0[#U9M'!<\>PMMEY!,!Y'=H.<G%V>LBM-)<08SO
MF *-2FMF4?+36)WMK;-V<:]?RJK^ F7#BUE'R61O(3\@3+& 2IE,;T=.<I E
MK%$(Y9B'[CIM"6EKN.:=Z<:.>6G(#" J7*)A%6:QKAK&URL54Q769.%K3B1=
MQ#F2JMQ4JT,\!1^_4 ')T#)*D,'I,!?3-M=:T+1_S^WBIES%KR3GG9X?'$RF
MBE++1UC5DDVRB:K<CT\"D9P5%1(3)*)E5$>PE$0$/@Z4N[@C+#9<@+'2"_Q.
M>'LO6OEARY+U'%N2;+#K5.B@G*5VD6B9C%52Q @H5-]&Q;AJH<OH[]C"(=$F
M>JTRB!#CZ!'[K74+=3/PJ&W<7=*Q9*I+&RG!+!'6B%E(*0%N;--,\M4&<JV:
MN!1,'Z)O#V_-TAVG8_13F%\P;NJ6?_XH=7T6?5:>]U;+R1ZB<K.5MJ]/M-W>
MR-8ROK;CW$;MY*0%KEJXBT91=!DY(R!JVHU$[U.3K(MSE44,0">(!((B E#2
M;U1$"64(DCF+[U7G\3?FT\SS?X+6*_-\?F>;^R.^^9Y@#XO'X_6O%X_%Z>_?
MOWZ>*[P/1'QC^WB.J%ZWFY;>1#DBX^LS;#Z%RF$JCK_EG%A9"4K54NS&(:5R
M(R2C8'\C)K3RCY!LW8M'ZPCX3)E*1,/CZDDF0MY%4!&$" 1KUC6-Z=A.YO)H
MWR(\@.6\]RI*I5<VX=Q57]8V%W=2*=6RCDBK1]^5<5*&)X5&X>N2DDP;.3)@
M'A*X#Q"'HZ9.&4B5(B<R,(BSZI26XW&YMGR;ZQY(WMO6/,N:S[84>(DJ-C76
M7"JKVM4.YP==<2TA!V:0KSB+=6-W*32\B)5%T'*9%4BD\) 'TBB'JRN,A X2
M01IK=6ISB:W[UAO%Q\;3ZQ:YV7-S_7G'[]:48H0T]+Q06!:/BX_Z/F#PI =$
M'RU%3?.IF$Q ](^GI2!?@EEF.$AQ;<NQ*<I7./..S2$WPUXYF'ZA2$4?2F+<
MB/W:A4R@4A3N7;Y58Q2%#L ";T!U>*X\CT4_&!9+Q'5"IN[M3S?;J:HY)U,E
M>*R(QM4,E!7ROY2EX^R-'O(\T%:82SIJM&YGBK %%W$,5,XG1/\ (./Y>PA)
M+AF/(]$XPB).2_$=4,/\+K?#_MQR%^[5]7/<4C[[_P L]E]M_N_T_BZ''@AK
MQ;M">+S39TY%,+9JULB=%]H;6Z'+U\H]!R#@/&5!A,D67"E0D&E=8N\L6R+B
MH6?M$)7Y-W(F73=/TDF0B(@4P^@.G*1!MHEE0A*!,A9KVI2?*GO;S/\ &WL;
MA;!M0W+R'L/,Y&I+&_.8.)Q)7S6$4R*1CA[!M8.&K*T@L8K=T<AS 03%[#W
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9]\_=M(_,_P"GZ'?H^_B@?JX+05UHN=?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex992102_v1.jpg
<TEXT>
begin 644 ex992102_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ &  ( P$1  (1 0,1 ?_$ '$  0
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>22TKC%G*5J]JF57*WF.4G 5M3-,$Z[<?)LFD?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex992103_v1.jpg
<TEXT>
begin 644 ex992103_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ #P 3 P$1  (1 0,1 ?_$ $T  0$
M       * 0$! 0                   000 0                     1
H 0                    #_V@ , P$  A$#$0 _ ) 4;P    '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex992104_v1.jpg
<TEXT>
begin 644 ex992104_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ $@ 2 P$1  (1 0,1 ?_$ (,   ,!
M      <("@D!  ,! 0                 ! P($$    P0%!1$!
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1+YL0ON]UWN[YO6%/6W;H_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %6 T8# 2(  A$! Q$!_\0
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M>O\ A33U;2-'>6-U^>_8;XX3_NCG/NV!]:V-*\7QR[8M041OT\U?NGZCM73
MQ7$.04DB<>Q#"F@>J/BO5-7U#6KYKS4KR:ZN'ZO*V?P'H/85U_@_X4Z_XK,=
MP\9L-.8Y^TSKRP_V%ZGZ\#WKWVW^&WA*VUUM7BT: 7).0IYC5O[P3H#^%=7T
M&!5N?8A0[G(^&?AOX;\+VAC@L8[J=UVRW%TH=W!ZCD8 ]A7'^,O@=I^H^9>>
M&Y%L;H\FU?\ U+GV[K^H^E>O45',R^56L?%NMZ!JOAV^:SU6REM9ATWCAAZJ
M>A'N*V_"/Q%U_P 'R*EI<>?99^:TG):/\/[I^GZU]4:OHFFZ]8/9:I9Q75NW
M\,@Z'U!Z@^XKP[QE\#+RR\R]\,R-=P#YC9R']ZO^Z>C?3@_6M%)/1F;@UJCT
MGP?\4= \6A(%E^Q:B1S:SL!N/^PW1OY^U=O7Q#/!<65RT-Q%)!/&V&1U*LI]
MP>17H_@WXS:UX?\ +M-6W:GIZC WM^^C'LW?Z'\Q2<.PU/N?2]%8?AOQ?HGB
MNT$^DWJ2L!EX6.)(_P#>7K^/2MRLS0**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ&[O+:PM9+F[GC@@C&7DE8
M*JCW)KQOQE\=88/,L_"T0FD'!O9E^0?[B]_J?R--)O83:6YZKKWB72/#-B;O
M5KV.WC_A4G+.?15')KP?QE\;M4U?S+/0%?3K,\&8G]^X^O1/PY]Z\UU/5;_6
MKY[W4KN6ZN'ZO(V3]!Z#V%=5X/\ A=K_ (M*3K%]BT\\FZG4@,/]A>K?R]ZT
M44M69N3>B.-_?75Q_P M)II6]V9V/ZDUZIX.^"&IZKLN_$#MIUH<$0#_ %SC
MW[+^//M7K_A'X=Z!X/C#V5OYU[C#7<^&D/T[*/I^M=92<^PU#N96A>'-(\-6
M0M-)L8K:/^(J,LY]68\D_6M6BBLS0**** "BLK4_$%CI@*N_F3?\\TY/X^E<
M;J?B*^U+*;_)A/\ RS0]?J>] '<?VUIWVS[+]KC\WTSQGTSTS3=9T'2_$-B;
M/5;**ZA/0..5/JIZ@^XKS>"WFN91%!&TCGH%&:[_ ,/V&I6,&V]N0R8^6'[V
MW\?Z4 >*^,?@;?Z?YEYX;D:^MQDFUD($J#V/1OT/UKR22.>TN&CD22&>)L%6
M!5E(_D:^WZYCQ7X"T'QA#C4;79= 82ZA^61?Q[CV.:T4^YFX=CQ/P=\:=8T/
MR[360^IV(XWLW[Z,>S?Q?0_G7O7AWQ7HWBJS^TZ1>I.!]^,\/'_O*>17SEXQ
M^$^O>%=]S$G]H:<.?/@4[D'^VO4?7D>]<78:C>:5>1WEA<RVUQ&<K)$Q4BFX
MJ6J$I..C/MJBO#O!WQV!\NS\518/07T"?^AH/YK^5>K7OC#P]I^C+J\^K6HL
MG&8Y%D#>9[*!R3["LW%HT4DS;K UWQKX=\-7$,&JZI#!-*0!'RS 'N0,X'N:
M\8\8_'+4-1\RT\.1M86QX-RX!F;Z=E_4_2O)I))[NX:21Y)IY&R68EF8G]2:
MM0[D.?8^VK>XM[VV2>WECG@E7*O&P96'L1UK"U3PG:W>Z6T(MYO0#Y#^';\*
M\P^$W@WQMIL\=]+>OI>EN=SVDZ[FF'^X?N?7@U[C4-69:=T>67VG76G2^7<Q
M%">A[-]#4FG:O>:9)FWE.S/S1MRI_"O2YX(KF)HIHUDC;JK#(KD]4\'D;I=.
M;(Z^2Y_D?\:0S5TOQ-9ZAMCE/D3GC:QX/T-;=>2S0RV\ACFC:-UZJPP:U]*\
M37FG;8Y#Y\ _@8\CZ&@#T.BJ&G:Q9ZFF8),/WC;AA^%7Z "BBB@#F_%7@70?
M%]N5U*T N ,)=1?+*GX]Q['(KP'QE\(]=\+^9=6JG4=-7GSH5^=!_MKU'U&1
M]*^HJ*I2:)<4SXDLKZ[TV\CN[&YEMKB,Y62)BK#\17LW@WXZNGEV7BJ+<O07
MT*\_\#0?S'Y5V?C+X1Z%XG\RZM5&G:DW/G0K\CG_ &UZ?B,'ZUX#XI\#:[X0
MN"FI6A,!.$NHOFB?\>Q]C@U=U(SM*)];:=J5EJUE'>:?=17-M(,K)$V0?_K^
MU6J^-/#WBG6?"U[]JTF]>!C]].J2#T93P:]X\&_&K2-;\NSUL+IM\>/,)_<.
M?J?N_C^=2X-%J:9ZG12*RNBNC!E89!!R"*6H+"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***.U 'R+XY\8:MXIUVZ-[<O]EBF98+8
M'"1@' X[G'>J7AOPAK?BR[\C2;-I54XDF;Y8X_\ >;^G6LS4O^0K>?\ 7=__
M $(U]2?"-0/AAHV !E9"<#K^\:MI/E6AC%<SU,GP=\&=%\/[+K5=NJ7XY&]?
MW,9]E[_4_D*]+  & , =!2T5DVV:I);!1112&%%%% !7+>+M4N;7R;6WD,8D
M4L[*<$CIBNIKB?&W_'_;?]<C_.@#F41Y9 B*SNQX &2372Z9X0GGQ)?,84Z^
M6OWC_A4?@P ZM+D=(3_,5W= %:SL+6PB\NVA6->Y'4_4]ZLT44 %%%% !7G/
MC'X/Z%XE\RZL573-0//F1+^[D/\ M)_48_&O1J*:;0FD]SX\\4>"M=\(W/EZ
MI9E8B<1W$?S1/]&_H<&N?SQCM7UO\30&^&VNY .+?(R/<5\DI_K%^HK6+NC&
M4;,['PA\,]?\7LDT,'V33R>;N<84C_9'5OPX]Z]_\(?#/P_X01)8(/M6H <W
M<X!8'_9'11].?>NN@4+;QJH 4*  !TXJ2LW)LU44@HHHJ2@HHHH J7^F6FI1
M;+F(-CHPX9?H:XS5/"EW99DMLW$(YX'S+]1W_"N^HH \C1WBD#(S(ZG@@X(K
MT/PSJ$VHZ66N&W21N4+?WN ?ZUQFO@#7KS'_ #TKI_!7_(*G_P"NY_\ 010(
MZ6BBB@84444 %17%O!=V\EO<PQS0R#:\<BAE8>A!J6B@#QOQE\#+2\\R]\,2
MBTGZFSE/[MC_ +)ZK^.1]*\.U?1=2T&^:RU2SEM;A?X9!U'J#T(]Q7VK7CW[
M0:C_ (1O26P-PNV&<?[!K2,G>QG**M<X_P"#/B_5K7Q79Z ]S)-IMT'40N<B
M)@I8%?3ITZ<U](U\G_";_DIVB_[[_P#HMJ^L*4]QPV"BBBH+"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ H[44=J /B74O\ D*WG_7=__0C7
MU+\)/^27Z+_NR?\ HUZ^6]2_Y"MY_P!=W_\ 0C7U)\)/^27Z+_NR?^C7K6>Q
ME#<[6BBBLC4**** "BBB@ KB?&W_ !_VW_7(_P Z[:N)\;?\?]M_UR/\Z (_
M!?\ R%IO^N)_F*[JN%\%_P#(6F_ZXG^8KNJ "BBB@ HHHH **** .4^)G_)-
MM=_Z]C_,5\DQ_P"L7ZBOK;XF?\DWUW_KV/\ ,5\D1_ZQ?J*UAL95-S[?B_U*
M?[HI],B_U*?[HI]9&H4444 %%%% !1110!YGK_\ R'KS_KI_2NG\%?\ (*G_
M .NY_P#017,>(/\ D/7G_73^E=/X*_Y!4_\ UW/_ *"*!'2T444#"BBB@ HH
MHH *\?\ V@_^1:TG_K\/_H!KV"O'_P!H/_D6M)_Z_#_Z :J.Y,MCR_X3?\E.
MT7_KH_\ Z+:OK"OD_P"$W_)3M%_ZZ/\ ^BVKZPIU-Q4]@HHHJ"PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]2G^Z*?3(O\ 4I_NBGUD:A1110 4444 %%%% 'F?B#_D/7G_ %T_I73^"O\
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MH&%%%% !1110 5X_^T'_ ,BSI/\ U^'_ - ->P5X_P#M!_\ (LZ3_P!?A_\
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MB?\ "NCAABMXEBAC6-%Z*HP*0S!TOPG:VFV6[(N)O[I'R#\._P"-="    ,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9=T=82%!)( '4FO,_&7QGT70/,M-)VZI?KP2C?N8S[M_%]!^8KQ_QA\4=?\
M%Q>!I?L6G$\6L#$!A_MMU;^7M7*Z7I.H:U?)9Z;9S75P_1(ER?J?0>YJU#N9
MN?8O^)/%VM^*[OS]6O7E4'*0KQ''_NKT_'K4GACP7KGBZY\K2K-GC4XDN'^6
M)/JWK[#)KUOP=\"H(-EYXIE$\G!%E"V$'^\W4_0<>YKV.UM+:QMH[:T@C@@C
M&$CC4*JCV IN:6P*#>K//O!WP=T/PYLNM0"ZIJ P=\J?NXS_ +*?U.?PKT?H
M,"BBLVVS1)+8****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4MD_O>KD>I_0?C51C=DRE9'U!I5V]_H]C>.H5[BW25E7H"R@_P!:N5E^&_\
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M_H9-3_\  AJ)1NPC-)'V!17Q_P#\)_XO_P"ADU/_ ,"&H_X6!XO_ .ADU/\
M\"&_QI>S8_:(^P**^1K/Q]XM>^MT;Q'J15I5!!N&Y&?K7US4RC8J,KA1114E
M!1110!1UG_D!:A_U[2?^@FOBFOM;6?\ D!:A_P!>TG_H)KXIK6F95#LOA3_R
M4W1/^NK_ /H#5]95\F_"G_DINB?]=6_] :OK*IJ;E4]@HHHJ"PHHHH ****
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M:UQE-;$O<^T/#?\ R*VD?]>4/_H K4K+\-?\BMI'_7E#_P"@"M2L#H04444
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MET*A'J+11169H%%%% !1110 4444 %%%% 'Q-JG_ "%[W_KN_P#Z$:M>&/\
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M5YAX9^"]AX:\16>L1:O<SR6K%A&\2@-E2.OXUZ?2FTWH.":6H4445)04444
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M44 <?\4O^2::Y_UQ'_H:U\EU]G^)=#C\2>';S1Y9FA2Z0*9%&2O(/3\*\O\
M^&>M,_Z#UW_WY7_&M(226IG.+;T/ *6O?O\ AGK3/^@]=_\ ?E?\:/\ AGK3
M/^@]=_\ ?E?\:KG1/(SP&BO?O^&>M,_Z#UW_ -^5_P :/^&>M,_Z#UW_ -^5
M_P :.=!R,\ K9\)?\CEH?_80@_\ 1BU[-_PSUIG_ $'KO_ORO^-6]+^!&G:7
MJ]GJ":W=2-:SI,$,2@,58''7VHYT'(SUJBBBL38**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3"BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
